Last reviewed · How we verify
NCT04000880: AMPLIFY
Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health
NA trial testing Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health in Breast Cancer in 603 participants. Participants enrolled and being followed up; not accepting new ones.
1 April 2025
Quick facts
| Lead sponsor | University of Alabama at Birmingham |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | supportive care |
| Enrollment | 603 |
| Start date | 4 March 2020 |
| Primary completion | 1 April 2025 |
| Estimated completion | 1 September 2025 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health
- Diet-Exercise
- Exercise-Diet
- Combined Diet and Exercise
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Endometrial Cancer — all drugs for Endometrial Cancer →
- Kidney Cancer — all drugs for Kidney Cancer →
Sponsor
University of Alabama at Birmingham
Who can join
50 and older, any sex, with Breast Cancer or Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research study will test the efficacy of interactive, web-based interventions that improve diet, physical activity and weight management changes among early stage survivors of breast, prostate, colorectal, endometrial, renal, thyroid, and ovarian cancers, as well as multiple myeloma and non-Hodgkin Lymphoma. Overarching outcomes also include physical function and performance, muscle mass, quality of life, and health utilities.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
A Narrative Review of the Role of Diet and Lifestyle Factors in the Development and Prevention of Endometrial Cancer.
Yasin HK, Taylor AH, Ayakannu T. · · 2021 · cited 41× · PMID 33946913 · DOI 10.3390/cancers13092149 -
Dietary interventions for adult cancer survivors.
Burden S, Jones DJ, Sremanakova J, Sowerbutts AM, et al · · 2019 · cited 41× · PMID 31755089 · DOI 10.1002/14651858.cd011287.pub2 -
Interventions for weight reduction in obesity to improve survival in women with endometrial cancer.
Agnew H, Kitson S, Crosbie EJ. · · 2023 · cited 16× · PMID 36971688 · DOI 10.1002/14651858.cd012513.pub3 -
Adapting MultiPLe behavior Interventions that eFfectively Improve (AMPLIFI) cancer survivor health: program project protocols for remote lifestyle intervention and assessment in 3 inter-related randomized controlled trials among survivors of obesity-related cancers.
Pekmezi D, Fontaine K, Rogers LQ, Pisu M, et al · · 2022 · cited 12× · PMID 35488238 · DOI 10.1186/s12885-022-09519-y -
Translating energy balance research from the bench to the clinic to the community: Parallel animal-human studies in cancer.
Garcia MB, Schadler KL, Chandra J, Clinton SK, et al · · 2023 · cited 11× · PMID 36825928 · DOI 10.3322/caac.21773 -
How Healthy Are the Diets of Cancer Survivors? Characteristics of Those Most at Risk and Opportunities for Improvement.
Kaur H, Pisu M, Pekmezi DW, Rogers LQ, et al · · 2025 · cited 3× · PMID 40359987 · DOI 10.6004/jnccn.2025.7012 -
Behind the Numbers: Cancer Survivor Recruitment by Demographics and Clinical Status.
Martin MY, Demark-Wahnefried W, Omairi I, Schoenberger-Godwin YM, et al · · 2026 · PMID 41998846 · DOI 10.1002/cam4.71782 -
Supporting Cancer Survivors in Making Healthful Lifestyle Changes.
Demark-Wahnefried W, Bail JR, Hoenemeyer T, Pekmezi DW, et al · · 2020 · PMID 41567983 · DOI 10.1080/10463356.2020.1720373
Verify or expand the search:
- PubMed search for NCT04000880
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other University of Alabama at Birmingham trials
Trials by the same sponsor.
- NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
- NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
- NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
- NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
- NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04000880 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
- Last refreshed: 12 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04000880.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing